These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10634357)

  • 1. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers.
    Newfield RS; Kalaitzoglou G; Licholai T; Chilton D; Ashraf J; Thompson EB; New MI
    J Clin Endocrinol Metab; 2000 Jan; 85(1):14-21. PubMed ID: 10634357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
    Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
    J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.
    Tomlinson JW; Draper N; Mackie J; Johnson AP; Holder G; Wood P; Stewart PM
    J Clin Endocrinol Metab; 2002 Jan; 87(1):57-62. PubMed ID: 11788623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F; Brue T; Conte-Devolx B
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifepristone for management of Cushing's syndrome.
    Morgan FH; Laufgraben MJ
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
    Nieman LK; Chrousos GP; Kellner C; Spitz IM; Nisula BC; Cutler GB; Merriam GR; Bardin CW; Loriaux DL
    J Clin Endocrinol Metab; 1985 Sep; 61(3):536-40. PubMed ID: 2991327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing's syndrome.
    Refetoff S; Van Cauter E; Fang VS; Laderman C; Graybeal ML; Landau RL
    J Clin Endocrinol Metab; 1985 Mar; 60(3):527-35. PubMed ID: 2982900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).
    Chu JW; Matthias DF; Belanoff J; Schatzberg A; Hoffman AR; Feldman D
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3568-73. PubMed ID: 11502780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid receptor blockers.
    Molitch ME
    Pituitary; 2022 Oct; 25(5):733-736. PubMed ID: 35507245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.
    Newfield RS; Spitz IM; Isacson C; New MI
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):399-404. PubMed ID: 11298094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of glucocorticoid receptors and HLA antigens in the pathogenesis of Cushing's syndrome].
    Davydova IV; Andrusenko AB
    Klin Med (Mosk); 1990 Jun; 68(6):115-9. PubMed ID: 2214620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of non-Cushingoid Cushing's syndrome].
    Yushita Y; Haraguchi T; Sakai H; Suzu H; Kanetake H; Saito Y
    Hinyokika Kiyo; 1990 Dec; 36(12):1429-33. PubMed ID: 1963757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-hour cycles of adrenocorticotropin and cortisol secretion in Cushing's disease.
    Schteingart DE; McKenzie AK
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1195-8. PubMed ID: 6252234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.
    Bertagna X; Bertagna C; Laudat MH; Husson JM; Girard F; Luton JP
    J Clin Endocrinol Metab; 1986 Sep; 63(3):639-43. PubMed ID: 3734034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.